Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma

Allergology International

Volumn 66, Issue 3, 2017, Pages 445-451

  Shimoda, Terufumi ^a   Odajima, Hiroshi ^a   Okamasa, Arisa ^b   Kawase, Minako ^b   Komatsubara, Masaki ^b   Mayer, Bhabita ^c   Yancey, Steven ^d   Ortega, Hector ^d  

^a FUKUOKA NATIONAL HOSPITAL   (Japan)

^b Development and Medical Affairs Division   (Japan)

^c GLAXOSMITHKLINE   (United Kingdom)

^d GLAXOSMITHKLINE   (United States)

Author keywords

Asthma; Mepolizumab; Placebo; Safety; Treatment efficacy

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN E; MEPOLIZUMAB; PLACEBO; ANTIASTHMATIC AGENT; BIOLOGICAL MARKER; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; AGED; ALLERGIC RHINITIS; ANTIBODY RESPONSE; ARTICLE; ASTHMA; BRONCHITIS; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DIARRHEA; DISEASE CONTROL; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ECZEMA; EMERGENCY CARE; EOSINOPHIL COUNT; FEMALE; FORCED EXPIRATORY VOLUME; GALLBLADDER DISEASE; HEADACHE; HEAT STROKE; HERPES ZOSTER; HOSPITALIZATION; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INFLUENZA; INJECTION SITE REACTION; JAPANESE (PEOPLE); LUNG FUNCTION; MALAISE; MALE; MIDDLE AGED; MIGRAINE; MINIMAL CLINICALLY IMPORTANT DIFFERENCE; MULTICENTER STUDY; OROPHARYNX PAIN; PEAK EXPIRATORY FLOW; PELVIS FRACTURE; PHASE 3 CLINICAL TRIAL; POST HOC ANALYSIS; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; ST. GEORGE RESPIRATORY QUESTIONNAIRE; UPPER RESPIRATORY TRACT INFECTION; VERY ELDERLY; YOUNG ADULT; CLINICAL TRIAL; DRUG ADMINISTRATION; EOSINOPHILIA; LEUKOCYTE COUNT; LUNG FUNCTION TEST; PATHOLOGY; RISK FACTOR; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; BIOMARKERS; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; EOSINOPHILIA; FEMALE; HUMANS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; QUALITY OF LIFE; RESPIRATORY FUNCTION TESTS; RISK FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85009505642     PISSN: 13238930     EISSN: 14401592     Source Type: Journal    
DOI: 10.1016/j.alit.2016.11.006     Document Type: Article

References (25)

1. Pakhale, S., Mulpuru, S., Boyd, M., Optimal management of severe/refractory asthma. Clin Med Insights Circ Respir Pulm Med 5 (2011), 37–47.
2. Ohta, K., Ichinose, M., Nagase, H., Yamaguchi, M., Sugiura, H., Tohda, Y., et al. Japanese guideline for adult asthma 2014. Allergol Int 63 (2014), 293–333.
3. Hasegawa, T., Koya, T., Sakagami, T., Toyabe, S., Kagamu, H., Arakawa, M., et al. Asthma control and management changes in Japan: questionnaire survey. Intern Med 51 (2012), 567–574.
4. World Health Organization. Bronchial Asthma. Available at: http://www.who.int/mediacentre/factsheets/fs206/en/. [accessed 11 June 2015].
5. von Bulow, A., Kriegbaum, M., Backer, V., Porsbjerg, C., The prevalence of severe asthma and low asthma control among Danish adults. J Allergy Clin Immunol Pract 2 (2014), 759–767.
6. Wenzel, S.E., Severe asthma in adults. Exp Lung Res, 31(Suppl 1), 2005, 22.
7. Pavord, I.D., Korn, S., Howarth, P., Bleecker, E.R., Buhl, R., Keene, O.N., et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 380 (2012), 651–659.
8. Chung, K.F., Wenzel, S.E., Brozek, J.L., Bush, A., Castro, M., Sterck, P.J., et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 43 (2014), 343–373.
9. Green, R.H., Brightling, C.E., McKenna, S., Hargadon, B., Parker, D., Bradding, P., et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 360 (2002), 1715–1721.
10. ten Brinke, A., Zwinderman, A.H., Sterk, P.J., Rabe, K.F., Bel, E.H., “Refractory” eosinophilic airway inflammation in severe asthma: effect of parenteral corticosteroids. Am J Respir Crit Care Med 170 (2004), 601–605.
11. Wenzel, S.E., Asthma: defining of the persistent adult phenotypes. Lancet 368 (2006), 804–813.
12. Zacharasiewicz, A., Wilson, N., Lex, C., Erin, E.M., Li, A.M., Hansel, T., et al. Clinical use of noninvasive measurements of airway inflammation in steroid reduction in children. Am J Respir Crit Care Med 171 (2005), 1077–1082.
13. Flood-Page, P., Swenson, C., Faiferman, I., Matthews, J., Williams, M., Brannick, L., et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 176 (2007), 1062–1071.
14. Flood-Page, P.T., Menzies-Gow, A.N., Kay, A.B., Robinson, D.S., Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 167 (2003), 199–204.
15. Ortega, H.G., Liu, M.C., Pavord, I.D., Brusselle, G.G., FitzGerald, J.M., Chetta, A., et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 371 (2014), 1198–1207.
16. Haldar, P., Brightling, C.E., Hargadon, B., Gupta, S., Monteiro, W., Sousa, A., et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 360 (2009), 973–984.
17. Nair, P., Pizzichini, M.M., Kjarsgaard, M., Inman, M.D., Efthimiadis, A., Pizzichini, E., et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 360 (2009), 985–993.
18. Bel, E.H., Wenzel, S.E., Thompson, P.J., Praza, C.M., Keene, O.N., Yancey, S.W., et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 371 (2014), 1189–1197.
19. Bjornsson, T.D., Wagner, J.A., Donahue, S.R., Harper, D., Karim, A., Khouri, M.S., et al. A review and assessment of potential sources of ethnic differences in drug responsiveness. J Clin Pharmacol 43 (2003), 943–967.
20. Huang, S.M., Temple, R., Is this the drug or dose for you? Impact and consideration of ethnic factors in global drug development, regulatory review, and clinical practice. Clin Pharmacol Ther 84 (2008), 287–294.
21. Yasuda, S.U., Zhang, L., Huang, S.M., The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies. Clin Pharmacol Ther 84 (2008), 417–423.
22. Chiba, K., Yoshitsugu, H., Kyosaka, Y., Iida, S., Yoneyama, K., Tanigawa, T., et al. A comprehensive review of the pharmacokinetics of approved therapeutic monoclonal antibodies in Japan: are Japanese phase I studies still needed?. J Clin Pharmacol 54 (2014), 483–494.
23. Korotzer, B., Ong, S., Hansen, J.E., Ethnic differences in pulmonary function in healthy nonsmoking Asian-Americans and European-Americans. Am J Respir Crit Care Med 161 (2000), 1101–1108.
24. Tsukamoto, N., Takahashi, N., Itoh, H., Pouliquen, I., Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin 5 monoclonal antibody, in healthy Japanese male subjects. Clin Pharmacol Drug Dev 5 (2015), 102–108.
25. Jones, P.W., Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur Respir J 19 (2002), 398–404.